Wall Street Banks Drawn Into Widening French Dividend Tax Audits
As part of their wider-ranging audits French tax officials are now questioning some overseas lenders with significant trading floors in Paris in a bid to learn more about the so-called Cum-Cum transactions, the people said. Those include Goldman Sachs Group Inc. and Bank of America Corp., they added, asking not to be identified because the proceedings are confidential.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
JPMorgan Lifts Arista Networks (ANET) PT to $130, Cites Strong Cloud Spending
Arista Networks Inc. (NYSE:ANET) is one of the most profitable growth stocks to buy according to billionaires. On July 17, JPMorgan increased its price target for Arista Networks from $110 to $130 while maintaining an Overweight rating. The revision is based on the firm's belief that strong spending in the cloud sector will drive growth for the company through H2 2025. In Q1 2025, Arista Networks' revenue reached ~$2 billion, which was a 27.6% increase year-over-year. Deferred revenue stood at $3.1 billion, which was a sequential increase from $2.8 billion. For Q2, Arista Networks provided revenue guidance of ~$2.1 billion. Earnings per share grew by 30% to $0.65. As of the end of the quarter, cash and investments totaled ~$8.15 billion. A technician at a workstation, preparing and calibrating a sensor for automotive microcontrollers. Arista Networks also secured significant new customer wins across various sectors in Q1. However, the increase in product deferred revenue points to potential volatility in customer deployment schedules. Later on July 31, Samik Chatterjee from JP Morgan also maintained a Buy rating on Arista Networks, with a price target of $130. Arista Networks Inc. (NYSE:ANET) develops, markets, and sells data-driven, client-to-cloud networking solutions for AI, data center, campus, and routing environments in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. While we acknowledge the potential of ANET as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
25 minutes ago
- Yahoo
Goldman Sachs Reduced the PT on Merck & Co., Inc. (MRK), Kept a Buy Rating
Merck & Co., Inc. (NYSE:MRK) is one of the Best Stocks to Invest in for High Returns. On July 30, Goldman Sachs analyst Asad Haider maintained a Buy rating on Merck & Co., Inc. (NYSE:MRK) while reducing the price target from $99 to $94. The analyst noted that despite recent complexities in the company's financial update released on July 29, the bottom line surpassed expectations. Moreover, the Gardasil vaccine franchise in the United States and China has been a concern, however, the company's new product Winrevair is showing strong growth potential. Management is optimistic about expanding its label and anticipates supportive data from the HYPERION trial later this year, which boosts confidence in future growth. A close-up of a person's hand holding a bottle of pharmaceuticals. Haider also highlighted the company's $3 billion optimization plan as another positive. Through this initiative the company aims to shift resources from slower-growth areas to new product launches and research and development. The analyst believes that while this might increase costs temporarily however, it supports long term expansion. Merck & Co., Inc. (NYSE:MRK) is a global healthcare company that develops and sells prescription medicines, vaccines, and animal health products. While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
25 minutes ago
- Yahoo
Celyad Oncology SA: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
MONT-SAINT-GUIBERT, Belgium, August 07, 2025--(BUSINESS WIRE)--Regulatory News: Celyad Oncology (Euronext: CYAD) (the "Company" or "Celyad Oncology"), today announces the below information following the issuance, on August 5, 2025, of 3,333,333 new shares of Celyad Oncology to an affiliate of Fortress Investment Group. As a result, the Company's share capital has been increased to 9,216,154.53 EUR and is represented by 44,761,905 shares. This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions. Figures – Modified on August 5, 2025, following the capital increase: Total amount of share capital (EUR) 9,216,154.53 Total Number of shares with single voting rights 35,893,530 Total Number of shares with double voting rights 8,868,375 Total Number of Shares 44,761,905 Total of voting rights 53,630,280 Total number of attributed warrants 3,856,134 Total number of shares with voting rights that could be created following the exercise of the attributed warrants 3,856,134 Total number of diluted shares (Outstanding shares + Warrants) 48,618,039 Total number of diluted shares with voting rights 57,486,414 Contact person for regulated information (financial, transparency) By law, any transparency declaration must be sent to our Company by email to the attention of Matthew Kane, Chief Executive Officer (CEO): investors@ Further questions about the content of this release can be sent to investors@ About Celyad Oncology Celyad Oncology is a cutting-edge biotechnology company focused primarily on unlocking the potential of its proprietary CAR-T technology platforms and intellectual property. The Company is headquartered in Mont-Saint-Guibert, Belgium. For more information, visit Celyad Oncology Forward-Looking Statement This release may contain forward-looking statements, including, without limitation, statements regarding beliefs about and expectations for the Company's updated strategic business model, including associated potential benefits, transactions and partnerships, statements regarding the potential value of the Company's IP, statements regarding the Company's financial statements and cash runway, statements regarding the Company's future fundraising plans, statements regarding the Company's hiring plans, and statements regarding the continuation of the Company's existence. The words "will," "potential," "continue," "target," "project," "should" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this release are based on management's current expectations and beliefs and are subject to a number of known and unknown risks, uncertainties and important factors which might cause actual events, results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks related to the material uncertainty about the Company's ability to continue as a going concern; the Company's ability to realize the expected benefits of its updated strategic business model; the Company's ability to develop its IP assets and enter into partnerships with outside parties; the Company's ability to enforce its patents and other IP rights; the possibility that the Company may infringe on the patents or IP rights of others and be required to defend against patent or other IP rights suits; the possibility that the Company may not successfully defend itself against claims of patent infringement or other IP rights suits, which could result in substantial claims for damages against the Company; the possibility that the Company may become involved in lawsuits to protect or enforce its patents, which could be expensive, time-consuming, and unsuccessful; the Company's ability to protect its IP rights throughout the world; the potential for patents held by the Company to be found invalid or unenforceable; and other risks identified in the latest Annual Report of Celyad Oncology. These forward-looking statements speak only as of the date of publication of this document and Celyad Oncology's actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad Oncology expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation. View source version on Contacts Investor & Media: David Georges, VP Finance and Administrationinvestors@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
